Kodiak Sciences (KOD) Why AMD fueled the stock 180% Higher
Kodiak Sciences stock surged over 170% following encouraging Phase 3 trial data for wet age-related macular degeneration treatments Zenkuda and KSI-501, which successfully met primary endpoints.
Biotechnology firm Kodiak Sciences (KOD) saw its stock surge more than 170% on Monday following encouraging data from its AMD trial. Following the completion of the Phase 3 DAYBREAK study focusing on wet AMD (age-related macular degeneration) and the release of substantial findings, Kodiak shares jumped from a previous close in the low $30s to end Monday near $87. The stock experienced a minor downward correction of about 3% the following day.
The company revealed that its two investigational treatments for wet age-related macular degeneration, Zenkuda and KSI-501, successfully achieved the primary endpoint in a late-stage clinical trial. Notably, Zenkuda showed “a potential new standard-of-care profile,” offering rapid relief following administration alongside sustained therapeutic effects.
The upward movement in Kodiak’s stock reflects the increasing market valuation of AI companies such as Advanced Micro Devices (AMD). Both equities advanced on Monday, pushing KOD’s year-to-date gains to 15%. Estimating the worldwide market for retinal vascular disease medications at $15 billion, the biotech enterprise seeks to secure a foothold in a fiercely competitive environment—highlighted by the late-July regulatory approval of Outlook Therapeutics’ Lytenava for wet AMD.
Buoyed by these recent clinical outcomes, Kodiak Sciences intends to submit a Biologics License Application for Zenkuda in the fourth quarter, which serves as the formal request seeking marketing authorization from regulators. Should this process succeed, Zenkuda will transition from being the company’s longest-standing pipeline candidate to its inaugural commercialized product.
At present, KOD operates as a pure catalyst battleground. UBS has issued a Buy rating alongside an $80 price target for Kodiak Sciences, suggesting that the Phase III wet AMD clinical trials for tarcocimab and KSI‑501 will likely demonstrate non‑inferiority compared to the established benchmark therapy, Eylea. The deciding factor lies in dosing convenience; if KOD’s therapies successfully extend treatment intervals, the commercial perspective transforms from a standard alternative to a significantly more convenient option, paving the way for premium pricing and robust uptake.
